99.78
-3.38(-3.28%)
Currency In USD
| Previous Close | 103.16 |
| Open | 102.95 |
| Day High | 103.52 |
| Day Low | 97.21 |
| 52-Week High | 122.2 |
| 52-Week Low | 45.91 |
| Volume | 641,407 |
| Average Volume | 763,563 |
| Market Cap | 6.66B |
| PE | -32.19 |
| EPS | -3.1 |
| Moving Average 50 Days | 106.02 |
| Moving Average 200 Days | 92.33 |
| Change | -3.38 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,061.05 as of February 21, 2026 at a share price of $99.78. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,761.03 as of February 21, 2026 at a share price of $99.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
GlobeNewswire Inc.
Jan 09, 2026 1:00 PM GMT
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194